Migraine play CoLucid raises $37.1M

CoLucid Pharmaceuticals Inc. (Durham, N.C.) raised $37.1 million in a series C round led by TVM Capital Life Science. New investors included Novo Ventures and Auriga Partners. Existing investors Pappas Ventures; Domain Associates; Care Capital; Triathlon Medical Ventures; and Pearl Street Ventures also participated.

CoLucid received an SPA from FDA last year for the Phase III SAMURAI trial of lasmiditan ( COL-144) to treat acute migraine. Lasmiditan is an oral selective agonist of serotonin (5-HT1F) receptor. ...